trial
as of 2026-07-01A Study To Evaluate The Effect Of A Supratherapeutic Dose Of Elpipodect (MK-8189) On The QTc Interval In Participants With Schizophrenia (MK-8189-019)
NCTId NCT05893862
at a glance
Phase 1 · Completed
Enrollment 107 (actual)
Sponsored by Merck Sharp & Dohme LLC
Primary completion 2024-02-22
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 1
Status
Completed
Enrollment
107 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Double
Start
2023-06-26
Primary completion
2024-02-22
Eligibility
ALL · 18 Years · 60 Years
Interventions & indications
Indications
Sponsors
Merck Sharp & Dohme LLCLead Sponsor
Sites
4 total
Glendale, United StatesOrange, United StatesHallandale, United StatesMarlton, United States
Facts & assertions
4 sourced
Enrollment
107
Phase
PHASE1
Primary Completion Date
2024-02-22
Status
COMPLETED
relationships
The graph out of here
drug
drug
drug
lead_sponsor
company
indication
indication
indication